S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

@article{Burbridge2013S49076IA,
  title={S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab},
  author={Mike F. Burbridge and C{\'e}line Bossard and Carine Saunier and Imre Fejes and Alain P. Bruno and St{\'e}phane L{\'e}once and Gilles Ferry and Georges Da Violante and François Bouzom and Val{\'e}rie Cattan and Anne Jacquet-Bescond and Paolo Maria Comoglio and Brian Paul Lockhart and Jean A. Boutin and Alex A. Cordi and Jean-Claude Ortuno and Alain Pierr{\'e} and John A. Hickman and Francisco H. Cruzalegui and S. Depil},
  journal={Molecular Cancer Therapeutics},
  year={2013},
  volume={12},
  pages={1749 - 1762}
}
Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been associated with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies. This study describes the preclinical characterization of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro… Expand
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
TLDR
This study demonstrates that S49076 has dual antitumor activity and can be used in combination with radiotherapy for the treatment of both MET-dependent and MET-independent tumors and supports the evaluation of combined treatment of S4906 with radiation in clinical trials without patient selection based on the tumor MET dependency status. Expand
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models12
TLDR
In all xenograft models studied, lucitanib demonstrated marked tumor growth inhibition due to potent inhibition of angiogenesis, suggesting that the simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors can be therapeutically advantageous. Expand
Discovery of a potent and selective Axl inhibitor in preclinical model.
TLDR
To clarify whether enzyme inhibition of Mer by a small molecule leads to retinal toxicity in mice, Axl/Mer inhibitors and Axl-selective inhibitors are designed and synthesized and a pyrimidine derivative is discovered, which selectively inhibited the activity of Axl over Mer without retinaloxicity at a dose of 100 mg/kg in mice. Expand
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
TLDR
AXL-targeted drugs, either as single agents or in combination with conventional chemotherapy or other small molecule inhibitors, are likely to improve the survival of many patients, however, future investigations into AXL molecular signalling networks and robust predictive biomarkers are warranted to select patients who could receive clinical benefit and to avoid potential toxicities. Expand
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
TLDR
This review summarizes the mechanisms and frequencies of MET aberrations in NSCLC, the efficacies and toxicities of MET-TKIs under clinical development, and the mechanisms of inherent and acquired resistance to MET- TKIs. Expand
In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways.
TLDR
It is suggested that Desacetylvinblastine monohydrazide potently inhibits angiogenesis-mediated tumor growth through blockage of the activation of VEGF/VEGFR2 and Gas6/Axl pathways and it might serve as a promising antiangiogenic agent for the cancer therapy. Expand
AXL kinase as a novel target for cancer therapy
TLDR
The data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis are highlighted, and future perspectives in this emerging field are highlighted. Expand
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
  • Mai Tanaka, D. Siemann
  • Medicine
  • International journal of molecular sciences
  • 2021
TLDR
The Gas6/Axl signaling pathway has been implicated to promote progression, metastasis, immune evasion, and therapeutic resistance in many cancer types and promising results have been observed in both preclinical and clinical settings when such agents are used alone or in combination therapy. Expand
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
TLDR
S49076 plus gefitinib demonstrated a good tolerability with limited anti-tumour activity and no tendency in term of activity appeared in any specific molecular subset and the data did not allow for identification of AXL overexpression as an oncogenic driver. Expand
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
TLDR
The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
TLDR
Increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation are reported. Expand
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
TLDR
It is shown that Axl knockdown reduces growth of lung and breast cancer xenograft tumors and the additive effect of Axl inhibition with anti-VEGF suggests that blocking Axl function could be an effective approach for enhancing antiangiogenic therapy. Expand
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
TLDR
The antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms, and the therapeutic potential of targeting c-Met with selective small-molecule inhibitors for the treatment of human cancers is shown. Expand
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
TLDR
It is revealed that both the FGFR2 and EGFR family signaling pathways are activated inFGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival. Expand
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
TLDR
GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptor currently in phase II clinical trials, restores lapatinib and trastuzumab sensitivity in these resistant cells that exhibit increased AXL expression. Expand
Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.
TLDR
The study clearly suggests that inhibition of c-Met activity can effectively sensitize osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling, thus enhancing cis platin chemosensitivity. Expand
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
TLDR
It is demonstrated that EGFR TKI-induced FGFR2 and FGFR3 are capable of mediating FGF2 and FGF7 stimulated ERK activation as well as FGF-stimulated transformed growth in the setting of EGfr TKIs and suggests that treatment of NSCLC patients with combinations of EGFR andFGFR specific TKis may be a strategy to enhance efficacy of single EGFR inhibitors. Expand
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
TLDR
This study is the first to implicate FGFR in the development of resistance to lapatinib in cancer, and suggests that FGFR-targeted therapy might become a promising salvage strategy after lapatinIB failure in patients with HER2-positive breast cancer. Expand
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
TLDR
It is predicted that gastric cancer tumors bearing constitutive activation of HER family members are poorly responsive to MET inhibition, even if this receptor is constitutively active. Expand
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
TLDR
It is shown for the first time that HGF-induced EGFR TK-inhibition is a very common mechanism in human cancers, and that the kinase-inactive EGFR directly interacts with and stabilizes several cancer-relevant proteins, including the receptor tyrosine kinases Axl and EphA2, and the CUB domain-containing protein-1. Expand
...
1
2
3
4
5
...